Evotec: Weak Performance, But Long-Term Potential Is There [Seeking Alpha]
Evotec SE (EVO)
NASDAQ:AMEX Investor Relations:
eatonvance.com
Company Research
Source: Seeking Alpha
Summary Evotec's 28% decline is due to negative EBITDA despite solid top-line revenue growth, highlighting the need for patience in speculative investments. The company is restructuring, focusing on biologics and partnerships with BMY and others, aiming for profitability by 2025 or later. Valuation remains tricky; I cut my price target to $11/share due to delayed market recovery and sluggish revenue recognition. Evotec is a speculative "buy" with high potential but significant risks; I recommend holding and watching for now, not buying more. Looking for more investing ideas like this one? Get them exclusively at iREIT®+HOYA Capital. Learn More » Images By Tang Ming Tung Dear readers/followers, Drug discovery company Evotec ( NASDAQ: EVO ) marks one of my worst performers this year. While the position in question is rather small, that is no excuse to not cover or update on the company - especially at such a lacking performance. I spend enough time talking about my wins
Show less
Read more
Impact Snapshot
Event Time:
EVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVO alerts
High impacting Evotec SE news events
Weekly update
A roundup of the hottest topics
EVO
News
- Comment on Media Report [Yahoo! Finance]Yahoo! Finance
- Comment on Media ReportAccesswire
- Evotec SE (NASDAQ: EVO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Evotec SE (EVOTF) Q3 2024 Earnings Call Highlights: Navigating Market Challenges with Strategic ... [Yahoo! Finance]Yahoo! Finance
- Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions [Yahoo! Finance]Yahoo! Finance